150 related articles for article (PubMed ID: 37196426)
21. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
22. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract][Full Text] [Related]
23. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
24. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
Shin JY; Ahn SM
J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
27. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
29. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
32. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
[TBL] [Abstract][Full Text] [Related]
33. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
[TBL] [Abstract][Full Text] [Related]
34. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
35. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
[TBL] [Abstract][Full Text] [Related]
36. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract][Full Text] [Related]
37. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract][Full Text] [Related]
38. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
[TBL] [Abstract][Full Text] [Related]
40. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway.
Huang F; Shi X; Hu M; Yan H; Li X; Ding Y; Zheng X; Cai X; Dai S; Xia Q; Cai Y
Eur J Pharmacol; 2024 May; 970():176493. PubMed ID: 38484925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
